- Home
- MKTW vs RNXT Comparison
MKTW vs RNXT Comparison
Compare MKTW & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- RNXT
- Stock Information
- Founded
- MKTW 1999
- RNXT 2012
- Country
- MKTW United States
- RNXT United States
- Employees
- MKTW N/A
- RNXT N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- MKTW Technology
- RNXT Health Care
- Exchange
- MKTW Nasdaq
- RNXT Nasdaq
- Market Cap
- MKTW 46.9M
- RNXT 44.0M
- IPO Year
- MKTW N/A
- RNXT 2021
- Fundamental
- Price
- MKTW $17.08
- RNXT $0.93
- Analyst Decision
- MKTW Hold
- RNXT Strong Buy
- Analyst Count
- MKTW 1
- RNXT 2
- Target Price
- MKTW $20.00
- RNXT $7.50
- AVG Volume (30 Days)
- MKTW 15.2K
- RNXT 360.0K
- Earning Date
- MKTW 11-06-2025
- RNXT 11-13-2025
- Dividend Yield
- MKTW 4.68%
- RNXT N/A
- EPS Growth
- MKTW N/A
- RNXT N/A
- EPS
- MKTW 2.55
- RNXT N/A
- Revenue
- MKTW $342,206,000.00
- RNXT $662,000.00
- Revenue This Year
- MKTW N/A
- RNXT $2,895.35
- Revenue Next Year
- MKTW N/A
- RNXT $313.04
- P/E Ratio
- MKTW $6.71
- RNXT N/A
- Revenue Growth
- MKTW N/A
- RNXT N/A
- 52 Week Low
- MKTW $9.08
- RNXT $0.75
- 52 Week High
- MKTW $21.74
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- MKTW 61.15
- RNXT 36.08
- Support Level
- MKTW $16.12
- RNXT $0.98
- Resistance Level
- MKTW $16.88
- RNXT $1.14
- Average True Range (ATR)
- MKTW 0.50
- RNXT 0.07
- MACD
- MKTW 0.33
- RNXT -0.02
- Stochastic Oscillator
- MKTW 88.46
- RNXT 8.69
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.